Medical/Pharmaceuticals
Datasea Announces Closing of $2.25 Million Registered Direct Offering
BEIJING, July 3, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative businesses in high-tech intelligent acoustics and 5G-Artificial Intelligence ("AI") multimodal communication technology inthe United States and China, today ...
2024-07-04 04:30
4873
Bloomage Ranks on World Brand Lab's China 500 Most Valuable Brands List
PARSIPPANY, N.J., July 2, 2024 /PRNewswire/ -- Bloomage has once again ranked on the "China's 500 Most Valuable Brands" list by World Brand Lab, a premier global brand value evaluation agency. This milestone not only affirms the strength of Bloomage's brand but also recognizes its long-term commi...
2024-07-02 21:00
2039
Datasea Announces Pricing of $2.25 Million Registered Direct Offering
BEIJING, July 2, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative businesses in high-tech intelligent acoustics and 5G-Artificial Intelligence ("AI") multimodal communication technology inthe United States and China, today ...
2024-07-02 20:30
4682
PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
* Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of PMC-403 DAEJEON, South Korea, July 2, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ:208340), a clinical-stage public company developing next generation therapeutic...
2024-07-02 11:02
2994
Noul Co., Ltd. Releases 2023-2024 Sustainability Report
* CEO David Lim: "Committed to achieving genuine ESG practices and outstanding business performance simultaneously" * First KOSDAQ-listed medical AI company to publish a sustainability report * Reflecting a commitment to AI technology for social impact and social responsibility YONGIN, South...
2024-07-02 10:52
3467
Altos Biologics Files for Approval of Aflibercept Biosimilar
DAEJEON, South Korea, July 1, 2024 /PRNewswire/ -- Alteogen Inc.
2024-07-02 08:00
4314
Datasea Enters into New Sales Agreements for its 5G AI Communications and High Tech Acoustic Segments Expecting $62 Million in Sales
The Three Agreements Support Continued Fiscal Year 2025 Revenue Growth for its Core AI-Based Businesses BEIJING, July 1, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative businesses in high-tech intelligent acoustics and 5G-A...
2024-07-01 21:30
5081
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
YANGZHOU, China, July 1, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, announced today that its board o...
2024-07-01 18:00
2652
IASO Bio Presented Clinical Data and Single-cell Analysis of Equecabtagene Autoleucel for the Treatment of Central Nervous System Autoimmunity in Oral Presentation at EAN Congress 2024
SHANGHAI, NANJING, CHINA, and SAN JOSE, Calif., July 1, 2024 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented the clinical data and single-cell an...
2024-07-01 15:43
1935
Comprehensively Covering Multiple Myeloma: IASO Bio's GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA
NANJING, China, SHANGHAI and SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, today announces thatthe investigational new d...
2024-06-28 18:59
2585
50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress
SHANGHAI, June 27, 2024 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carc...
2024-06-28 10:30
2323
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 26, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2024-06-27 07:08
2532
The Future of Telehealth Relies on Seamless UC&C Monitoring
* IR launches a healthcare bundle to meet the demands of proactive communication monitoring in healthcare organizations. SYDNEY, June 26, 2024 /PRNewswire/ -- IR (ASX:IRI), a leading provider of global performance management and analytics for Unified Communications and Collaboration (UC&C), h...
2024-06-26 21:30
2964
bioSeedin Expanded Global Licensing and Partnership Opportunities at 2024 BIO International Convention
NEWARK, Del., June 26, 2024 /PRNewswire/ -- bioSeedin, a flourishing global licensing and consulting platform, captivated attendees as an esteemed exhibitor at the BIO International Convention, the preeminent global biotech gathering. This prestigious event unfolded inSan Diego, spanning from Jun...
2024-06-26 21:00
1887
Neurophet to present brain stimulation simulation study at OHBM 2024
- Presents a poster identifying tDCS effects for patients with AD and cognitively normal people - Showcases brain imaging treatment planning software for electric brain stimulation Neurophet tESplan Plus SEOUL, South Korea, June 26, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI...
2024-06-26 21:00
2536
Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
The prospectively defined, double-blind analysis of biomarker-positive patients with mild Alzheimer's disease showed more rapid clinical progression in biomarker-positive patients, highlighting the suitability of elevated pTau for selecting patients in the on-going XanaMIA phase2b trial SYDNEY, ...
2024-06-26 20:56
2859
Fufang E'jiao Syrup's Breakthrough Research on Cancer-Related Fatigue Receives "Special Excellence Award" at 2024 ASCO Annual Meeting
CHICAGO, June 26, 2024 /PRNewswire/ -- The 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), a significant event in the global oncology community, was grandly held inChicago, USA, from May 31 to June 4, 2024. ASCO has announced the list of outstanding abstracts for 2024, wh...
2024-06-26 18:42
1915
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EG...
2024-06-26 12:36
2463
Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever
* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...
2024-06-26 09:17
2539
ONO PHARMA USA Announces Support for Conquer Cancer®, the ASCO Foundation
Conquer Cancer Supports Cancer Research and Education CAMBRIDGE, Mass., June 25, 2024 /PRNewswire/ -- ONO PHARMA USA today announced it will provide a sponsorship to Conquer Cancer®, the ASCO Foundation, with$1 million funding to advance cancer research and education. Conquer Cancer is a glob...
2024-06-25 21:00
1840
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 280 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 260 media titles]
2026-02-17 14:16